Medical College of Qingdao University, Shandong Province, China.
BMC Gastroenterol. 2010 Dec 21;10:145. doi: 10.1186/1471-230X-10-145.
HLA-DRB1 allele polymorphisms have been reported to be associated with hepatocellular carcinoma susceptibility, but the results of these previous studies have been inconsistent. The purpose of the present study was to explore whether specific HLA-DRB1 alleles (DRB107, DRB112, DRB1*15) confer susceptibility to hepatocellular carcinoma.
Case-control studies on HLA-DRB1 alleles association with HCC were searched up to January 2010 through a systematic review of the literature. The odds ratios (ORs) of HLA-DRB1 allele distributions in patients with hepatocellular carcinoma were analyzed against healthy controls. The meta-analysis software REVMAN 5.0 was applied for investigating heterogeneity among individual studies and for summarizing all the studies. Meta-analysis was performed using fixed-effect or random-effect methods, depending on absence or presence of significant heterogeneity.
Eight case-control studies were included in the final analysis. Among the 3 HLA-DRB1 alleles studied, DRB107 and DRB112 were significantly associated with the risk of HCC in the whole populations (OR = 1.65, 95% CI: 1.08-2.51, P = 0.02 and OR = 1.59, 95% CI: 1.09-2.32, P = 0.02, respectively). No significant association was established for DRB115 allele with HCC in the whole populations. Subgroup analysis by ethnicity showed that DRB107, DRB112 and DRB115 alleles significantly increased the risk of hepatocellular carcinoma in Asians (OR = 2.10, 95% CI: 1.06-4.14, P = 0.03; OR = 1.73, 95% CI: 1.17-2.57, P = 0.006 and OR = 2.88, 95%CI: 1.77-4.69, P <0.001, respectively).
These results support the hypothesis that specific HLA-DRB1 alleles might influence the susceptibility of hepatocellular carcinoma. Large, multi-ethnic confirmatory and well designed studies are needed to determine the host genetic determinants of hepatocellular carcinoma.
HLA-DRB1 等位基因多态性与肝细胞癌易感性相关,但先前的研究结果并不一致。本研究旨在探讨特定 HLA-DRB1 等位基因(DRB107、DRB112、DRB1*15)是否与肝细胞癌易感性相关。
通过系统综述检索截至 2010 年 1 月 HLA-DRB1 等位基因与 HCC 关联的病例对照研究。分析肝癌患者 HLA-DRB1 等位基因分布的优势比(OR)与健康对照组进行比较。采用 Meta-analysis 软件 REVMAN 5.0 分析个体研究之间的异质性,并对所有研究进行总结。根据是否存在显著异质性,采用固定效应或随机效应方法进行 Meta 分析。
最终纳入 8 项病例对照研究。在所研究的 3 个 HLA-DRB1 等位基因中,DRB107 和 DRB112 在全人群中与 HCC 的发病风险显著相关(OR = 1.65,95%CI:1.08-2.51,P = 0.02 和 OR = 1.59,95%CI:1.09-2.32,P = 0.02)。在全人群中,DRB115 等位基因与 HCC 无显著相关性。按种族进行的亚组分析显示,DRB107、DRB112 和 DRB115 等位基因在亚洲人群中显著增加了肝细胞癌的发病风险(OR = 2.10,95%CI:1.06-4.14,P = 0.03;OR = 1.73,95%CI:1.17-2.57,P = 0.006 和 OR = 2.88,95%CI:1.77-4.69,P <0.001)。
这些结果支持特定 HLA-DRB1 等位基因可能影响肝细胞癌易感性的假说。需要进行大规模、多民族的验证性和精心设计的研究,以确定肝细胞癌的宿主遗传决定因素。